De novo mutations in histone-modifying genes in congenital heart disease
- PMID: 23665959
- PMCID: PMC3706629
- DOI: 10.1038/nature12141
De novo mutations in histone-modifying genes in congenital heart disease
Abstract
Congenital heart disease (CHD) is the most frequent birth defect, affecting 0.8% of live births. Many cases occur sporadically and impair reproductive fitness, suggesting a role for de novo mutations. Here we compare the incidence of de novo mutations in 362 severe CHD cases and 264 controls by analysing exome sequencing of parent-offspring trios. CHD cases show a significant excess of protein-altering de novo mutations in genes expressed in the developing heart, with an odds ratio of 7.5 for damaging (premature termination, frameshift, splice site) mutations. Similar odds ratios are seen across the main classes of severe CHD. We find a marked excess of de novo mutations in genes involved in the production, removal or reading of histone 3 lysine 4 (H3K4) methylation, or ubiquitination of H2BK120, which is required for H3K4 methylation. There are also two de novo mutations in SMAD2, which regulates H3K27 methylation in the embryonic left-right organizer. The combination of both activating (H3K4 methylation) and inactivating (H3K27 methylation) chromatin marks characterizes 'poised' promoters and enhancers, which regulate expression of key developmental genes. These findings implicate de novo point mutations in several hundreds of genes that collectively contribute to approximately 10% of severe CHD.
Figures
Comment in
-
Exome sequencing in congenital heart disease points to importance of DNA methylation.Circ Cardiovasc Genet. 2013 Oct;6(5):522. doi: 10.1161/CIRCGENETICS.113.000325. Circ Cardiovasc Genet. 2013. PMID: 24129593 No abstract available.
-
Congenital heart disease: entering a new era of human genetics.Circ Res. 2014 Feb 14;114(4):598-9. doi: 10.1161/CIRCRESAHA.113.303060. Circ Res. 2014. PMID: 24526674
References
-
- Pedersen MT, Helin K. Histone demethylases in development and disease. Trends Cell Biol. 2010;20:662–671. doi:10.1016/j.tcb.2010.08.011. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 HG006546/HG/NHGRI NIH HHS/United States
- 5U54HG006504/HG/NHGRI NIH HHS/United States
- P30 DK079310/DK/NIDDK NIH HHS/United States
- U01 HL098162/HL/NHLBI NIH HHS/United States
- U01 HL098153/HL/NHLBI NIH HHS/United States
- U01-HL098147/HL/NHLBI NIH HHS/United States
- F30 HL123238/HL/NHLBI NIH HHS/United States
- T32 GM007205/GM/NIGMS NIH HHS/United States
- U01 HL098123/HL/NHLBI NIH HHS/United States
- U01-HL098123/HL/NHLBI NIH HHS/United States
- U01-HL098162/HL/NHLBI NIH HHS/United States
- U01 HL098163/HL/NHLBI NIH HHS/United States
- U01-HL098188/HL/NHLBI NIH HHS/United States
- U01 HL098188/HL/NHLBI NIH HHS/United States
- U01-HL098163/HL/NHLBI NIH HHS/United States
- P30 HD018655/HD/NICHD NIH HHS/United States
- U54 HG006504/HG/NHGRI NIH HHS/United States
- U01-HL098153/HL/NHLBI NIH HHS/United States
- UM1 HL098166/HL/NHLBI NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
- T32 GM082771/GM/NIGMS NIH HHS/United States
- U01 HL098147/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
